AASHTO M 300-22 PDF

AASHTO M 300-22 PDF

Name:
AASHTO M 300-22 PDF

Published Date:
2022

Status:
Active

Description:

Standard Specification for Inorganic Zinc-Rich Primer

Publisher:
American Association of State Highway and Transportation Officials

Document status:
Active

Format:
Electronic (PDF)

Delivery time:
10 minutes

Delivery time (for Czech version):
200 business days

SKU:
aashto-m-300-22_2566568

Choose Document Language:
26.40 €
Need Help?

This specification covers self-curing, inorganic zinc-rich primers for use on steel surfaces.

Intended Use of the Primers:

Types I and II are intended for use on bridges, similar structural steel, and other ferrous metal surfaces subject to corrosive atmospheric environments such as marine, industrial, and high humidity.


File Size : 1 file , 450 KB
Note : This product is unavailable in Ukraine, Russia, Belarus
Number of Pages : 10
Published : 2022

History

AASHTO M 300-22
Published Date: 2022
Standard Specification for Inorganic Zinc-Rich Primer
26.40 €
AASHTO M 300-21
Published Date: 2021
Standard Specification for Inorganic Zinc-Rich Primer
23.40 €

Related products

AASHTO T 185-23
Published Date: 2023
Standard Method of Test for Early Stiffening of Hydraulic Cement (Mortar Method) (ASTM Designation: C359-21)
20.40 €
AASHTO M 335-19 (2023)
Published Date: 2019
Standard Specification for Steel-Reinforced Polyethylene (PE) Ribbed Pipe, 300- to 1500-mm (12- to 60-in.) Diameter
26.70 €
AASHTO T 49-22
Published Date: 2022
Standard Method of Test for Penetration of Bituminous Materials (ASTM Designation: D5/D5M-13)
AASHTO T 362-17 (2021)
Published Date: 2017
Standard Method of Test for Quantitative Determination of the Percentage of Lime in Hot Mix Asphalt (HMA)
19.80 €

Best-Selling Products

Alzheimer's Disease Report
Published Date: 12/01/2018
2398.50 €
Cystic Fibrosis Disease Report
Published Date: 04/01/2019
2398.50 €
Multiple Sclerosis Disease Report
Published Date: 12/01/2018
2398.50 €
Non-Alcoholic Steatohepatitis Disease Report
Published Date: 12/01/2018
2398.50 €
Non-Hodgkin's Lymphoma Disease Report
Published Date: 12/01/2018
2398.50 €